Windtree Therapeutics, Inc. (NASDAQ:WINT) Files An 8-K Financial Statements and Exhibits

Item 9.01.

Cautionary Note Regarding Forward-looking
Statements:

To the extent that statements in the press release, presentation
materials and this Current Report on Form 8-K are not strictly
historical, including statements about the Companys clinical
development programs, including AEROSURF, business strategy,
outlook, objectives, plans, intentions, goals, future financial
conditions, future collaboration agreements, the success of the
Companys product development activities, or otherwise as to
future events, such statements are forward-looking, and are made
to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. All such forward-looking
statements are subject to certain risks and uncertainties that
could cause actual results to differ materially from the
statements made. Such risks and others are further described in
the Companys filings with the Securities and Exchange Commission
including the most recent reports on Forms 10-K, 10-Q and 8-K,
and any amendments thereto.

WINDTREE THERAPEUTICS INC /DE/ Exhibit
EX-99.1 2 ex99-1.htm EXHIBIT 99.2 ex99-2.htm Exhibit 99.1       Windtree Announces Top-Line Results from AEROSURF® Phase 2b Clinical Trial for the Treatment of Respiratory Distress Syndrome (RDS) in Premature Infants   -Company to Hold Conference Call Today at 4:30 p.m. EDT-   WARRINGTON,…
To view the full exhibit click here
About Windtree Therapeutics, Inc. (NASDAQ:WINT)

Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.